Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

被引：1

作者：

Rizk, Mohamed ^{[1
]}

Rizq, Ola ^{[2
]}

Oshima, Motohiko ^{[1
]}

Nakajima-Takagi, Yaeko ^{[1
]}

Koide, Shuhei ^{[1
]}

Saraya, Atsunori ^{[3
]}

Isshiki, Yusuke ^{[4
]}

Chiba, Tetsuhiro ^{[5
]}

Yamazaki, Satoshi ^{[6
]}

Ma, Anqi ^{[7
,8
]}

Jin, Jian ^{[7
,8
]}

Iwama, Atsushi ^{[1
]}

Mimura, Naoya ^{[9
]}

机构：

[1] Univ Tokyo, Inst Med Sci, Div Stem Cell & Mol Med, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan

[4] Oami Municipal Hosp, Dept Hematol, Chiba, Japan

[5] Chiba Univ Hosp, Dept Gastroenterol, Chiba, Japan

[6] Univ Tokyo, Inst Med Sci, Div Stem Cell Biol, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan

[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA

[9] Chiba Univ Hosp, Dept Transfus Med & Cell Therapy, Chiba, Japan

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122157

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4400

引用

页数：3

共 50 条

[21] A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Nylund, Patrick
Parraga, Alba Atienza
Haglof, Jakob
De Bruyne, Elke
Menu, Eline
Garrido-Zabala, Berta
Ma, Anqi
Jin, Jian
Oberg, Fredrik
Vanderkerken, Karin
Kalushkova, Antonia
Jernberg-Wiklund, Helena
CELL DEATH & DISEASE, 2021, 12 (02)
[22] A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Patrick Nylund
Alba Atienza Párraga
Jakob Haglöf
Elke De Bruyne
Eline Menu
Berta Garrido-Zabala
Anqi Ma
Jian Jin
Fredrik Öberg
Karin Vanderkerken
Antonia Kalushkova
Helena Jernberg-Wiklund
Cell Death & Disease, 12
[23] EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma
Guo, Shushan
Tang, Qiongwei
Gao, Xuejie
Hu, Liangning
Hu, Ke
Zhang, Hui
Zhang, Qikai
Lai, Yue
Liu, Yujie
Wang, Zhuning
Chang, Shuaikang
Zhang, Yifei
Hu, Huifang
An, Dong
Peng, Yu
Cai, Haiyan
Shi, Jumei
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (07): : 1055 - 1064
[24] Inhibition of the histone methyl transferase EZH2 causes viability defects in multiple myeloma
Arora, Shilpi
Balasubramanian, Vidya
Williamson, Kaylyn
Gehling, Victor
Nasveschuk, Chris
Vaswani, Rishi
Busby, Jennifer
Garapaty, Shivani
Iyer, Priya
Zhao, Feng
Campbell, Robert
Cummings, Richard
Audia, Jim
Harmange, J. C.
Albrecht, Brian
Cook, Andrew
Dakin, Les
Normant, Emmanuel
Trojer, Patrick
CANCER RESEARCH, 2014, 74 (19)
[25] Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1
Hernández-Muñoz, I
Taghavi, P
Kuijl, C
Neefjes, J
van Lohuizen, M
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (24) : 11047 - 11058
[26] Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression
Yoshida, Kazuhiro
Toden, Shusuke
Ravindranathan, Preethi
Han, Haiyong
Goel, Ajay
CARCINOGENESIS, 2017, 38 (10) : 1036 - 1046
[27] Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations
Mensah, Afua Adjeiwaa
Valente, Sergio
Matkovic, Milos
Sartori, Giulio
Falzarano, Chiara
Tarantelli, Chiara
Cascione, Luciano
Pileri, Stefano A.
Cavalli, Andrea
Mai, Antonello
Bertoni, Francesco
CANCER RESEARCH, 2022, 82 (12)
[28] Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition
Thomas, Daniel
Sinha, Subarna
Yu, Linda
Jung, Namyoung
Dai, Bo
Gentles, Andrew J.
Feinberg, Andrew P.
Dill, David
Majeti, Ravindra
BLOOD, 2014, 124 (21)
[29] Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
Shinohara, Haruka
Sawado, Rie
Nakagawa, Makoto
Hattori, Ayuna
Yamagata, Kazutsune
Tauchi, Kimiharu
Ito, Jumpei
Kuwahara, Yasumichi
Okuda, Tsukasa
Ogawa, Chitose
Kitabayashi, Issay
MOLECULAR THERAPY ONCOLYTICS, 2022, 27 : 14 - 25
[30] Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Drew, Allison E.
Motwani, Vinny
Campbell, John E.
Tang, Cuyue
Smith, Jesse J.
Chesworth, Richard
Copeland, Robert A.
Raimondi, Alejandra
Ribich, Scott
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →